Natera (NASDAQ:NTRA) Insider John Fesko Sells 339 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 339 shares of the company’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $63,715.05. Following the transaction, the insider owned 152,408 shares of the company’s stock, valued at approximately $28,645,083.60. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

John Fesko also recently made the following trade(s):

• On Thursday, August 14th, John Fesko sold 678 shares of Natera stock. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88.
• On Monday, July 28th, John Fesko sold 1,710 shares of Natera stock. The stock was sold at an average price of $139.81, for a total transaction of $239,075.10.

Natera Trading Up 0.6%

Shares of NASDAQ NTRA opened at $188.02 on Thursday. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $196.63. The stock has a market cap of $25.81 billion, a PE ratio of -98.44 and a beta of 1.74. The company has a 50-day moving average of $169.97 and a 200 day moving average of $159.37.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same period in the prior year, the company posted ($0.30) EPS. The firm’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD boosted its holdings in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Norges Bank acquired a new position in shares of Natera in the 2nd quarter worth approximately $277,749,000. Nuveen LLC acquired a new position in shares of Natera in the 1st quarter worth approximately $113,375,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after acquiring an additional 732,156 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NTRA shares. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $200.00 price objective on shares of Natera in a research note on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Barclays reaffirmed an “overweight” rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Wells Fargo & Company began coverage on shares of Natera in a report on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $196.81.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.